APOE and Alzheimer disease: Similar experiments were performed in ApoE4+/+ or ApoE3+/+ mouse models with 5xFAD background with AD-related pathological, neuro-inflammatory, and behavioral phenotypes manifesting at 4–8 months of age [48, 49].